

In the Claims:

Please amend claims 94, 96, 98, 100, 101, 107-109, and 112 as shown. Please cancel claims 95 and 99. The listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-93. (Cancelled)

94. (Currently Amended) A method for therapeutically reducing aqueous humor inflow by selectively inhibiting sodium-hydrogen antiport activity in the eye of a human or animal subject, the method comprising:

therapeutically administering to ciliary epithelial cells of the eye of the subject having a trabecular network a pressure-modulating amount of at least one sodium-hydrogen exchange-1 (NHE) (NHE-1) inhibitor sufficient to selectively inhibit cellular antiport activity, the NHE-1 inhibitor displaying an inhibitor constant (Ki) characteristic of NHE-1 antiport blockers inhibitors, no higher than from 0.068 ±0.002 to 0.25 ±0.02 μM; thereby, inhibiting activity of the sodium-hydrogen antiport(s); and as a result, reducing net inflow in aqueous humor formation.

95. (Cancelled).

96. (Currently Amended) The method of claim 94, wherein the NHE-1 inhibitor is an amiloride analogue for which the Ki against NHE-1 antiport does not exceed 0.25 ±0.02 μM.

97. (Previously Presented) The method of claim 94, wherein the pharmaceutical composition further comprises an inhibitor of a Na⁺-K⁺-2Cl⁻ symport.

98. (Currently Amended) The method of claim 97, wherein the Na⁺-K⁺-2Cl⁻ symport inhibitor is bumetanide administered in combination with an inhibitor of anion exchanger isoform 2 (AE2).

99. (Cancelled).

100. (Currently Amended) The method of claim 99 claim 98, wherein the inhibitor of anion exchanger isoform 2 is 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS).

101. (Currently Amended) The method of claim 94, wherein the pharmaceutical composition further comprises at least one compound selected from the group consisting of miotics, beta blockers, carbonic anhydrase inhibitors, and [[a]] latanoprost ~~precursor~~
~~prostaglandins.~~

102. (Previously Presented) The method of claim 94, wherein administration of the pharmaceutical composition is topical, intravitreous, via an ocular insert, or via an implanted reservoir.

103. (Previously Presented) The method of claim 94, wherein the human or animal subject has glaucoma.

104. (Previously Presented) The method of claim 94, wherein the human or animal subject has elevated intraocular pressure or low intraocular pressure, as compared with normal pressure for that patient, such that antiport regulation therapy is needed.

Claims 105-106. (Cancelled).

107. (Currently Amended) The method of claim 96, wherein the NHE-1 inhibitor is selected from the group consisting of an ethyl-isopropyl-amiloride (EIPA), dimethylamiloride (DMA), HOE694, and methylpropylamiloride.

108. (Currently Amended) A therapeutic method for regulating salt uptake or release by ciliary epithelial cells in an eye of a human or animal subject, wherein the subject has a trabecular network, the method comprising ~~selectively~~ controlling or modulating the function of one or more antiports of the ciliary epithelial cells of the aqueous humor by:

therapeutically administering to the cells a modulating amount of an NHE-1 inhibitor sufficient to ~~selectively~~ inhibit cellular antiport activity, the NHE-1 (~~NHE~~) inhibitor to selectively inhibit cellular antiport activity, the NHE-1 inhibitor displaying an inhibitor constant (Ki) characteristic of NHE-1 antiport ~~blockers~~ inhibitors, no higher than from 0.068 ± 0.002 to 0.25 ± 0.02 μM ; thereby,

regulating salt uptake or release in aqueous humor formation; and
reducing net inflow.

109. (Currently Amended) The method of claim 108, wherein the modulating effect is reversible upon cessation of administration of the NHE-1 inhibitor.

110. (Previously Presented) The method of claim 108, wherein the pharmaceutical composition is administered to the cells *in vitro* or *in vivo*.

111. (Cancelled).

112. (Currently Amended) The method of claim 108, wherein the NHE-1 inhibitor comprises an amiloride analogue for which the Ki against NHE-1 antiport does not exceed 0.25 ±0.02 μM.

113. (Previously Presented) The method of claim 112, wherein the amiloride analogue is selected from the group consisting of ethyl-isopropyl-amiloride (EIPA), dimethylamiloride (DMA), HOE694, and methylpropylamiloride.

114. (Cancelled).

115. (Previously Presented) The method of claim 108, wherein an anion is transferred into the ciliary epithelial cells of the aqueous humor to block native chloride channels.

116. (Previously Presented) The method of claim 115, wherein the anion comprises cyclamate.